1-8 of 8
Petra Pichler
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety and Effectiveness in Treatment Naive CLL Patients with or without High Risk Features Treated with Veno Under Real-World Conditions in Austria, Germany, and Switzerland

Ingo Schwaner, Holger F. Hebart, Christoph Losem, Thomas Wolff, Caroline Lehmann, Johannes Huelsenbeck, Burkhard Schmidt, Petra Pichler, Davide Rossi
Journal: Blood
Blood (2023) 142 (Supplement 1): 4654.
https://doi.org/10.1182/blood-2023-174387
Published: 2023
Journal Articles

Feasibility and Safety of the First-in-Human Chemotherapy-Light Combination of Rituximab, Polatuzumab Vedotin and Glofitamab in Previously Untreated Aggressive B-Cell Lymphoma Patients Above 60 Years of Age Ineligible for a Fully Dosed R-CHOP - R-Pola-Glo/Ikf-t062, a Study of the Austrian Group for Medical Tumor Therapy (AGMT-NHL-16) and the German Lymphoma Alliance (GLA2022-10)

Thomas Melchardt, Rebecca I Wurm-Kuczera, Bettina Altmann, Petra Pichler, Manuel Orlinger, Michael Panny, Luisa Wohn, Andreas Rosenwald, Dirk Hellwig, Sascha Dietrich, Bertram Glass, Georg Lenz, Ulrich Keller, Marita Ziepert, Richard Greil, Bjoern Chapuy
Journal: Blood
Blood (2023) 142 (Supplement 1): 1734.
https://doi.org/10.1182/blood-2023-188854
Published: 2023
Journal Articles

Real-World Outcomes and Treatment Patterns in AL-Amyloidosis in Austria: An Analysis from the Austrian Interdisciplinary Amyloidosis Registry (AIDA)

Wolfgang Willenbacher, Hermine Agis, Maria-Theresia Krauth, Carlos Rodriguez-Torres, Irene Strassl, Nicolas Dominik Verheyen, Victoria Hoeller, Philpp Darling, Petra Pichler, Sarah Rittler, Roman Weger, Ella Willenbacher
Journal: Blood
Blood (2023) 142 (Supplement 1): 6749.
https://doi.org/10.1182/blood-2023-187598
Published: 2023
Journal Articles

Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study

Clinical Trials & Observations
David Belada, Katerina Kopeckova, Juan Miguel Bergua Burgues, Don Stevens, Marc André, Ernesto Perez Persona, Petra Pichler, Philipp B. Staber, Marek Trneny, Johannes Duell, Maeve Waldron-Lynch, Steve Wagner, Amitava Mukhopadhyay, Maren Dirnberger-Hertweck, John M. Burke, Grzegorz S. Nowakowski
Journal: Blood
Blood (2023) 142 (16): 1348–1358.
https://doi.org/10.1182/blood.2023020637
Published: 2023
Includes: Supplemental data
Journal Articles

Real-World Effectiveness and Safety of Venetoclax in Combination with Obinutuzumab in Treatment-Naive CLL Patients - Data from the Observational Study Verve

Ingo Schwaner, Holger Hebart, Christoph Losem, Thomas Wolff, Kirsten Famulla, Johannes Huelsenbeck, Burkhard Schmidt, Petra Pichler, Davide Rossi, Thomas Noesslinger
Journal: Blood
Blood (2022) 140 (Supplement 1): 12412–12413.
https://doi.org/10.1182/blood-2022-162273
Published: 2022
Journal Articles

Ninreal - a Real World (RW) Comparison of Ixazomib Triplets and IMiD Duplets, in Relapsed and Refractory Multiple Myeloma (RRMM) from the Austrian Myeloma Registry (AMR)

Wolfgang Willenbacher, Petra Pichler, Irene Strassl, Maria-Theresa Krauth, Hermine Agis, Siegfried Sormann, Bernd L. Hartmann, Klaus Podar, Roman Weger, Ella Willenbacher
Journal: Blood
Blood (2022) 140 (Supplement 1): 13194–13195.
https://doi.org/10.1182/blood-2022-165366
Published: 2022
Journal Articles

First-Mind: Primary Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

David Belada, Katerina Kopeckova, Juan Miguel Bergua Burgues, Don Stevens, Marc André, Ernesto Pérez Persona, Petra Pichler, Philipp B. Staber, Marek Trneny, Bettina Brackertz, Neha Shah, Andrea Sporchia, John M. Burke, Grzegorz S. Nowakowski
Journal: Blood
Blood (2021) 138 (Supplement 1): 3556.
https://doi.org/10.1182/blood-2021-148354
Published: 2021
Journal Articles

A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Analysis of the Safety Run-in Phase

David Belada, MD PhD, Grzegorz S. Nowakowski, MD, Juan Miguel Bergua Burgues, MD, Marc André, MD, Katerina Kopeckova, MD, Don A. Stevens, MD, Marek Trněný, MD Prof, Ernesto Pérez Persona, Petra Pichler, Pia Klöpfer, Bettina Brackertz, Emanuel Lohrmann, MD, Anirban Lahiry, Neha Shah, Günter Fingerle-Rowson, MDPhD, Wolfram Brugger, John M. Burke, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 27–28.
https://doi.org/10.1182/blood-2020-139788
Published: 2020